**Core Concept**
Metropathia hemorrhagica is a condition characterized by excessive hemorrhaging in the gastrointestinal tract, often associated with liver disease, particularly cirrhosis. The pathophysiology involves an imbalance of coagulation and fibrinolysis, leading to an increase in fibrinolytic activity and a decrease in platelet count.

**Why the Correct Answer is Right**
The treatment of metropathia hemorrhagica focuses on stabilizing the coagulation cascade and reducing fibrinolysis. This is typically achieved with **tranexamic acid**, which inhibits plasminogen activators and reduces fibrinolysis, thereby promoting clot formation and stabilizing the patient. **Octreotide** may also be used to reduce portal pressure and improve coagulopathy.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it does not directly address the underlying pathophysiology of metropathia hemorrhagica. **Anticoagulants** would further exacerbate the condition by increasing fibrinolysis and bleeding risk.
**Option B:** This option is incorrect as **platelet transfusions** may be necessary in cases of severe thrombocytopenia but do not address the underlying coagulopathy and fibrinolysis imbalance.
**Option C:** This option is incorrect as **vasopressin** may actually worsen the condition by increasing portal pressure and exacerbating coagulopathy.

**Clinical Pearl / High-Yield Fact**
In patients with liver disease, metropathia hemorrhagica can be triggered by stress, including surgery, trauma, or infection. Early recognition and treatment are crucial to prevent severe bleeding and mortality.

**Correct Answer:** D. Octreotide